Espirito Santo Investment Bank has initiated coverage on Cipla with a buy rating and target price of Rs 380 citing improving operational performance and growing inhaler franchise.
The real gem in Cipla is its respiratory franchise,which we believe offers a sustainable competitive advantage that has not yet been fully appreciated by the market,the bank said in a research note.
It sees inhalers’ valuation impact on the company at 60 rupees per share. At 1:41 pm,shares of Cipla were up 0.72 per cent at 334 rupees.
Company INFO More on Cipla
Stocks More on Cipla


